Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 903,658
  • Shares Outstanding, K 239,063
  • Annual Sales, $ 332,310 K
  • Annual Income, $ -51,750 K
  • EBIT $ -29 M
  • EBITDA $ -28 M
  • 60-Month Beta 1.01
  • Price/Sales 2.63
  • Price/Cash Flow 152.33
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 87.92% (+12.10%)
  • Historical Volatility 89.75%
  • IV Percentile 9%
  • IV Rank 3.57%
  • IV High 719.03% on 04/09/25
  • IV Low 64.56% on 01/10/25
  • Expected Move (DTE 14) 0.43 (11.44%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 5,762
  • Volume Avg (30-Day) 4,250
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 108,942
  • Open Int (30-Day) 97,999
  • Expected Range 3.36 to 4.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.14
  • Number of Estimates 4
  • High Estimate 0.38
  • Low Estimate -0.03
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +240.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.42 +56.39%
on 11/06/25
4.03 -5.96%
on 12/01/25
+0.94 (+32.98%)
since 11/04/25
3-Month
2.30 +64.78%
on 10/08/25
4.03 -5.96%
on 12/01/25
+1.26 (+49.80%)
since 09/04/25
52-Week
0.69 +447.29%
on 05/15/25
4.03 -5.96%
on 12/01/25
+0.13 (+3.55%)
since 12/04/24

Most Recent Stories

More News
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR,...

ESPR : 3.79 (+0.26%)
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference

ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37 th Annual Healthcare Conference in New York on December...

ESPR : 3.79 (+0.26%)
HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

TORONTO , Nov. 18, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and...

ESPR : 3.79 (+0.26%)
HLS.TO : 4.91 (+0.20%)
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization...

ESPR : 3.79 (+0.26%)
HLS.TO : 4.91 (+0.20%)
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

– Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis...

ESPR : 3.79 (+0.26%)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion’s...

ESPR : 3.79 (+0.26%)
Esperion Therapeutics: Q3 Earnings Snapshot

Esperion Therapeutics: Q3 Earnings Snapshot

ESPR : 3.79 (+0.26%)
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

– Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy’s...

ESPR : 3.79 (+0.26%)
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR)...

ESPR : 3.79 (+0.26%)
Esperion to Participate in Jefferies Global Healthcare Conference - London

ANN ARBOR, Mich., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Jefferies Global Healthcare Conference – London on November 18, 2025,...

ESPR : 3.79 (+0.26%)

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

See More

Key Turning Points

3rd Resistance Point 4.03
2nd Resistance Point 3.97
1st Resistance Point 3.88
Last Price 3.79
1st Support Level 3.73
2nd Support Level 3.67
3rd Support Level 3.58

See More

52-Week High 4.03
Last Price 3.79
Fibonacci 61.8% 2.76
Fibonacci 50% 2.36
Fibonacci 38.2% 1.97
52-Week Low 0.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar